Cargando…

Upregulated Immunogenic Cell-Death-Associated Gene Signature Predicts Reduced Responsiveness to Immune-Checkpoint-Blockade Therapy and Poor Prognosis in High-Grade Gliomas

Background: Immunogenic cell death (ICD) has emerged as a potential mechanism mediating adaptive immune response and tumor immunity in anti-cancer treatment. However, the signature of ICD in high-grade gliomas (HGGs) remains largely unknown, and its relevance to immunotherapies is still undetermined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xin, Guo, Dongfang, Yang, Xi, Chen, Rui, Jiang, Qingming, Zeng, Zhen, Li, Yu, Li, Zhenyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688114/ https://www.ncbi.nlm.nih.gov/pubmed/36429083 http://dx.doi.org/10.3390/cells11223655

Ejemplares similares

A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma
por: Yan, Xiuwei, et al.
Publicado: (2022)

Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma
por: Cai, Jiayang, et al.
Publicado: (2022)

A novel immunogenic cell death signature for the prediction of prognosis and therapies in glioma
por: Zhang, Jianhua, et al.
Publicado: (2023)

A 2-Gene Signature Related to Interferon-Gamma Predicts Prognosis and Responsiveness to Immune Checkpoint Blockade of Glioma
por: Li, Yongzhe, et al.
Publicado: (2022)

An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
por: Cao, Wenpeng, et al.
Publicado: (2023)

A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma
por: Liu, Wentao, et al.
Publicado: (2021)

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
por: Reilley, Matthew J., et al.
Publicado: (2019)

Correlation of microrna-372 upregulation with poor prognosis in human glioma
por: Li, Gang, et al.
Publicado: (2013)

A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma
por: Xiao, Youchao, et al.
Publicado: (2020)

Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas
por: Kuang, Yirui, et al.
Publicado: (2023)

Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients
por: Zhu, Hua, et al.
Publicado: (2022)

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas
por: Zhang, Hongbo, et al.
Publicado: (2020)

Identification and Validation of a Seizure-Free-Related Gene Signature for Predicting Poor Prognosis in Lower-Grade Gliomas
por: Li, Jinxing, et al.
Publicado: (2021)

Immunogenic cell stress and injury versus immunogenic cell death: implications for improving cancer treatment with immune checkpoint blockade
por: Sriram, Ganapathy, et al.
Publicado: (2022)

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
por: Zeng, Zhirui, et al.
Publicado: (2022)

Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors
por: Singh, Mohit Pratap, et al.
Publicado: (2021)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Downregulation of LUZP2 Is Correlated with Poor Prognosis of Low-Grade Glioma
por: Li, Yong, et al.
Publicado: (2020)

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
por: Decraene, Brecht, et al.
Publicado: (2022)

Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients
por: Lim, Jaejoon, et al.
Publicado: (2019)

Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
por: Zhang, Jiulong, et al.
Publicado: (2022)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Upregulation of the APOBEC3 Family Is Associated with a Poor Prognosis and Influences Treatment Response to Raf Inhibitors in Low Grade Glioma
por: Luo, Cheng, et al.
Publicado: (2021)

Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas
por: Fan, Kun, et al.
Publicado: (2017)

Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
por: Stump, Courtney T., et al.
Publicado: (2021)

Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma
por: Kurupati, Raj K., et al.
Publicado: (2018)

Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy
por: Sun, Zhiqiang, et al.
Publicado: (2022)

Elevated CD44 expression predicts poor prognosis in patients with low-grade glioma
por: Dong, Qiang, et al.
Publicado: (2019)

Publisher Correction: Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
por: Decraene, Brecht, et al.
Publicado: (2022)

High Expression of PLAGL2 is Associated With Poor Prognosis in High-Grade Glioma
por: Wang, Gang, et al.
Publicado: (2022)

MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma
por: Xiao, Feng, et al.
Publicado: (2023)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)

Transformable prodrug nanoplatform via tumor microenvironment modulation and immune checkpoint blockade potentiates immunogenic cell death mediated cancer immunotherapy
por: Yang, Weijing, et al.
Publicado: (2023)

High-expression of Galactosidase alpha is correlated with poor prognosis and immune infiltration in low-grade glioma
por: Zhang, Yi, et al.
Publicado: (2023)

Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas
por: Ye, Liguo, et al.
Publicado: (2021)

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
por: Niewolik, Jacqueline, et al.
Publicado: (2022)

Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma
por: Jiang, Silin, et al.
Publicado: (2023)

Prognosis and immune response of a cuproptosis-related lncRNA signature in low grade glioma
por: Xu, Yifan, et al.
Publicado: (2022)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
por: Wan, Yanzhi, et al.
Publicado: (2023)

Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
por: Jeong, Seong Dong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e25onmkpjhjrm9h3cuv5rujcc9